ACRV

1.15017.86%
PB

Peter Blume-Jensen

Co-Founder, Chairman of the Board, CEO, President & Acting Chief Scientific Officer

Mr. Peter Blume-Jensen, MD, PhD., is Member of Advisory Board of Bio-AI Health Inc. He served as a Member of Advisory Board at Kernal Biologics, Inc. until February 2025. Mr. Blume-Jensen is the Founder, Chairman, President, Chief Executive Officer and Acting Chief Scientific Officer of Acrivon Therapeutics, Inc. since October 2020. He is a Clinical Advisor of Cancer Drug Development. He has extensive experience in oncology R&D and oncogenic kinase signaling. From 2001 to 2008, he was Department Head at Serono, US and later at Merck & Co, Inc., where he established and led integrated oncology drug programs into the clinic. Since 2008 he was Vice President, Ext. Sci. Affairs and Global Therapeutic Area Advisor for Oncology at Daiichi Sankyo, Inc. He co-led the scientific due diligence and M&A resulting in the acquisition of Plexxikon. From 2010 to 2014, he was CSO for Metamark Genetics, where he built R&D and a novel, scripted proteomics tissue imaging platform. Here he led 4 clinical studies culminating with the blinded validation and launch of ProMark®, an outcome-predictive prostate cancer biopsy test included under NCCN guidelines and coverage. From 2014 to 2018, he was CSO for XTuit Pharmaceuticals, where he established a novel prodrug platform in collaboration with Dr Jeremiah Johnson, MIT, continued at Window Therapeutics. He is the inventor of the AP3 platform and the OncoSignature® patient selection method. He serves on the SAB for several private biotech companies and academic institutions. His review “Oncogenic Kinase Signaling (Nature, 2001) is a citation classic in the field of clinical medicine. Mr. Blume-Jensen received his MD from Copenhagen University Medical School, Denmark, his PhD from The Ludwig Institute for Cancer Research, Uppsala, Sweden and conducted his Post-Doctoral Fellowship under Tony Hunter at the Salk Institute, La Jolla, CA.

Positions